Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | GSTP1 | P09211 | 12/20 | 0.39 |
| ▸ | GSTM2 | P28161 | 11/20 | 0.39 |
| ▸ | IDO1 | P14902 | 3/20 | 0.37 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.37 |
| ▸ | G6PD | P11413 | 1/20 | 0.36 |
| ▸ | CASP6 | P55212 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3021920 | 0.83 | MEN1 (0.49) | MEN1KMT2AKCNH2GSTP1GSTM2 | |
| SCHEMBL3016679 | 0.83 | MEN1 (0.49) | MEN1KMT2AKCNH2GSTP1GSTM2 | |
| SCHEMBL26054240 | 0.77 | MEN1 (0.56) | MEN1KMT2AGSTP1GSTM2 | |
| SCHEMBL17914175 | 0.76 | MEN1 (0.63) | MEN1KMT2AGSTP1GSTM2IDO1 | |
| SCHEMBL6259333 | 0.76 | MEN1 (0.54) | MEN1KMT2AGSTP1GSTM2 | |
| SCHEMBL3014278 | 0.76 | GSTM2 (0.63) | MEN1KMT2AGSTM2IDO1USP2 | |
| SCHEMBL3492762 | 0.75 | MEN1 (0.55) | MEN1KMT2AKCNH2GSTP1GSTM2 | |
| SCHEMBL3025724 | 0.74 | GSTP1 (0.43) | MEN1KMT2AGSTP1GSTM2IDO1 | |
| SCHEMBL14140891 | 0.74 | MEN1 (0.54) | MEN1KMT2AKCNH2GSTP1GSTM2 | |
| SCHEMBL31135832 | 0.73 | MEN1 (0.56) | MEN1KMT2AGSTP1GSTM2IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8569011-B2 | Fluorescent derivatives of polyamines, method for preparing same and applications thereof as diagnosis tools in the treatment of cancerous tumors | PIERRE FABRE MEDICAMENT (FR) | 2013-10-29 | — | — | US | claimed |
| US-20120252059-A1 | FLUORESCENT DERIVATIVES OF POLYAMINES, METHOD FOR PREPARING SAME AND APPLICATIONS THEREOF AS DIAGNOSIS TOOLS IN THE TREATMENT OF CANCEROUS TUMORS | ANNEREAU JEAN-PHILIPPE (FR) | 2012-10-04 | — | — | US | claimed |
| US-20100202975-A1 | NOVEL FLUORESCENT DERIVATIVES OF POLYAMINES, METHOD FOR PREPARING SAME AND APPLICATIONS THEREOF AS DIAGNOSIS TOOLS IN THE TREATMENT OF CANCEROUS TUMORS | PIERRE FABRE MEDICAMENT (FR) | 2010-08-12 | — | — | US | claimed |
| US-8569011-B2 | Fluorescent derivatives of polyamines, method for preparing same and applications thereof as diagnosis tools in the treatment of cancerous tumors | PIERRE FABRE MEDICAMENT (FR) | 2013-10-29 | — | — | US | disclosed |
| US-20120252059-A1 | FLUORESCENT DERIVATIVES OF POLYAMINES, METHOD FOR PREPARING SAME AND APPLICATIONS THEREOF AS DIAGNOSIS TOOLS IN THE TREATMENT OF CANCEROUS TUMORS | ANNEREAU JEAN-PHILIPPE (FR) | 2012-10-04 | — | — | US | disclosed |
| US-20100202975-A1 | NOVEL FLUORESCENT DERIVATIVES OF POLYAMINES, METHOD FOR PREPARING SAME AND APPLICATIONS THEREOF AS DIAGNOSIS TOOLS IN THE TREATMENT OF CANCEROUS TUMORS | PIERRE FABRE MEDICAMENT (FR) | 2010-08-12 | — | — | US | disclosed |
| EP-2183230-A1 | NOVEL FLUORESCENT DERIVATIVES OF POLYAMINE, METHOD FOR PREPARING SAME AND APPLICATIONS THEREOF AS DIAGNOSIS TOOLS IN THE TREATMENT OF CANCEROUS TUMOURS | Pierre Fabre Medicament (FR) | 2010-05-12 | — | — | EP | disclosed |
| WO-2009013360-A9 | NOVEL FLUORESCENT DERIVATIVES OF POLYAMINE, METHOD FOR PREPARING SAME AND APPLICATIONS THEREOF AS DIAGNOSIS TOOLS IN THE TREATMENT OF CANCEROUS TUMOURS | PIERRE FABRE MEDICAMENT (FR) | 2010-02-18 | — | — | WO | disclosed |
| WO-2009013360-A1 | NOVEL FLUORESCENT DERIVATIVES OF POLYAMINE, METHOD FOR PREPARING SAME AND APPLICATIONS THEREOF AS DIAGNOSIS TOOLS IN THE TREATMENT OF CANCEROUS TUMOURS | PIERRE FABRE MEDICAMENT (FR) | 2009-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100202975-A1 | NOVEL FLUORESCENT DERIVATIVES OF POLYAMINES, METHOD FOR PREPARING SAME AND APPLICATIONS THEREOF AS DIAGNOSIS TOOLS IN THE TREATMENT OF CANCEROUS TUMORS | SRM, SMOX, SLCO2B1 | MEN1 405/4885KMT2A 1682/4885KCNH2 192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.